This trialstudies pre-op progestin therapy for endometrial cancer patients to see if it helps shrink the tumor. Histology and clinical/molecular data will be compared.
- Endometrial Cancer
1 Primary · 1 Secondary · Reporting Duration: 3 years
Side Effects for
Awards & Highlights
1 Treatment Group
Arm 1 - Megestrol
1 of 1
73 Total Participants · 1 Treatment Group
Primary Treatment: Arm 1 - Megestrol · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · Female Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How hazardous is the administration of Megestrol to human subjects in Arm 1?
"Given the early stage of this trial, there is limited evidence in support of the safety and efficacy of Megestrol treatment. Our team at Power have thus assigned a score of 1 to Arm 1 - Megestrol." - Anonymous Online Contributor
Are there currently any avenues for prospective participants to join this investigation?
"Affirmative. Visible on clinicaltrials.gov, this experiment began recruiting patients after being posted on July 5th 2022 and was last edited November 14th 2022. In total, 73 participants are required from a single medical facility." - Anonymous Online Contributor
What is the current recruitment number for this scientific experiment?
"Affirmative. The information on clinicaltrials.gov confirms that this medical trial is actively seeking participants. It was initially posted on July 5th 2022 and the most recent update took place November 14th 2022, with 73 candidates needed from one location." - Anonymous Online Contributor